TY - JOUR
T1 - The treatment of hypertension during pregnancy
T2 - When should blood pressure medications be started?
AU - Scantlebury, Dawn C.
AU - Schwartz, Gary L.
AU - Acquah, Letitia A.
AU - White, Wendy M.
AU - Moser, Marvin
AU - Garovic, Vesna D.
N1 - Funding Information:
Acknowledgments The project described was supported by Award Number P-50 AG44170 (V.D. Garovic) from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The writing of the manuscript and the decision to submit it for publication were solely the authors’ responsibilities.
PY - 2013/11
Y1 - 2013/11
N2 - Hypertensive pregnancy disorders (HPD) are important causes of maternal and fetal morbidity and mortality worldwide. In addition, a history of HPD has been associated with an increased risk for maternal cardiovascular disease later in life, possibly because of irreversible vascular and metabolic changes that persist beyond the affected pregnancies. Therefore, treatment of HPD may not only improve immediate pregnancy outcomes, but also maternal long-term cardiovascular health. Unlike the recommendations for hypertension treatment in the general population, treatment recommendations for HPD have not changed substantially for more than 2 decades. This is particularly true for mild to moderate hypertension in pregnancy, defined as a blood pressure of 140-159/90-109 mm Hg. This review focuses on the goals of therapy, treatment strategies, and new developments in the field of HPD that should be taken into account when considering blood pressure targets and pharmacologic options for treatment of hypertension in pregnant women.
AB - Hypertensive pregnancy disorders (HPD) are important causes of maternal and fetal morbidity and mortality worldwide. In addition, a history of HPD has been associated with an increased risk for maternal cardiovascular disease later in life, possibly because of irreversible vascular and metabolic changes that persist beyond the affected pregnancies. Therefore, treatment of HPD may not only improve immediate pregnancy outcomes, but also maternal long-term cardiovascular health. Unlike the recommendations for hypertension treatment in the general population, treatment recommendations for HPD have not changed substantially for more than 2 decades. This is particularly true for mild to moderate hypertension in pregnancy, defined as a blood pressure of 140-159/90-109 mm Hg. This review focuses on the goals of therapy, treatment strategies, and new developments in the field of HPD that should be taken into account when considering blood pressure targets and pharmacologic options for treatment of hypertension in pregnant women.
KW - Antihypertensive agents
KW - Blood pressure medications
KW - Cardiovascular diseases in women
KW - Hypertension
KW - Pregnancy induced
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84886935137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886935137&partnerID=8YFLogxK
U2 - 10.1007/s11886-013-0412-0
DO - 10.1007/s11886-013-0412-0
M3 - Article
C2 - 24057769
AN - SCOPUS:84886935137
SN - 1523-3782
VL - 15
JO - Current cardiology reports
JF - Current cardiology reports
IS - 11
M1 - 412
ER -